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Insulin resistance, with adipose tissue dysfunction, is one of the hallmarks of metabolic syndrome. We have reported a metabolic
syndrome-like phenotype in heme oxygenase (HO)-2 knockout mice, which presented with concurrent HO-1 deficiency and were
amenable to rescue by an EET analog. Apo A-I mimetic peptides, such as L-4F, have been shown to induce HO-1 expression and
decrease oxidative stress and adiposity. In this study we aimed to characterize alleviatory eﬀects of HO-1 induction (if any) on
metabolic imbalance observed in HO-2 KO mice. In this regard, HO-2(−/−) mice were injected with 2 mg/kg/day L-4F, or vehicle,
i.p., for 6 weeks. As before, compared to WT animals, the HO-2 null mice were obese, displayed insulin resistance, and had elevated
blood pressure. These changes were accompanied by enhanced tissue (hepatic) oxidative stress along with attenuation of HO-1
expression and activity and reduced adiponectin, pAMPK, and LKB1 expression. Treatment with L-4F restored HO-1 expression
and activity and increased adiponectin, LKB1, and pAMPK in the HO-2(−/−) mice. These alterations resulted in a decrease in blood
pressure, insulin resistance, blood glucose, and adiposity. Taken together, our results show that a deficient HO-1 response, in a state
with reduced HO-2 basal levels, is accompanied by disruption of metabolic homeostasis which is successfully restored by an HO-1
inducer.

1. Introduction
Obesity, metabolic syndrome, and associated insulin resistance are major contributors to cardiovascular disease, the
leading cause of mortality in the United States [1]. Insulin
resistance is characterized by hyperglycemia and increase
in lipolysis and free fatty acid levels and increased hepatic
triglyceride secretion and sterol-regulatory element-binding
protein-1 (SREBP-1) [2, 3]. SREBPs are transcription factors
known to regulate genes involved in fatty acid and cholesterol
synthesis and are regulated by pAMPK [3, 4]. AMPK is
phosphorylated and activated by the major kinase, LKB1,
and acts as a metabolic checkpoint that is suppressed in
hyperglycemic conditions [4–8]. Hyperglycemia and associated increase in reactive oxygen species (ROS) are known

to decrease HO levels [1, 9, 10]. There are two forms of
HO, the inducible HO-1 and the constitutively expressed
HO-2 [4, 11]. HO-1 and -2 catabolize heme into equimolar
concentrations of carbon monoxide, bilirubin, and free iron,
generating an antioxidant eﬀect and increasing nitric oxide
(NO) bioavailability and providing cardiovascular protection
[4, 11]. HO-1 is the major cytoprotective moiety of the HO
system because of its rapid inducibility by a broad spectrum
of compounds and conditions including stress. However,
recent studies using HO-2(−/−) mice suggest that HO-2 is
also critical for cellular homeostasis and for upregulation of
HO-1 [4, 11]. When HO-1 increases, levels of antioxidant
and anti-inflammatory molecules increase and the level of
reactive oxygen species (ROS) decreases [9]. The benefits of
increased levels of HO-1 protein include the prevention of
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high blood pressure, decreased vasoconstrictors, increased
vasodilators, and the inhibition of oxidative stress [1, 10, 12].
The eﬀects of HO are also associated with an increase in
adiponectin, a protein hormone that modulates many metabolic processes and can improve cardiovascular function
while downregulating proinflammatory factors [1, 9, 13, 14].
Adiponectin exists in three diﬀerent forms trimer, hexamer,
and high molecular weight (HMW) with HMW adiponectin
being the form that attenuates cardio-vascular disease [1, 14].
In both, obese subjects and animals, the plasma levels of
adiponectin are inversely related to insulin sensitivity [4, 13,
15, 16]. The upregulation of HO-1 is associated with an
increase in adiponectin levels and correlates with decreased
inflammatory cytokines, IL-1, IL-6, and TNFα [1, 9].
Recently developed HO-2 null mice have displayed characteristics of a metabolic syndrome-like phenotype with enhanced systemic inflammatory and oxidative stress response.
Curiously, these mice also demonstrate a failure to induce
stress-dependent HO-1 upregulation along with suppression
of adiponectin levels. That attenuated HO-1 upregulation in
an HO-2 null mouse is accompanied by metabolic imbalance
led us to examine the eﬀects of an HO-1 inducer in such a
setting. The apo-A1 mimetic peptide, L-4f, was administered
to HO-2 null mice so as to rescue HO-1 expression.
This apo-A1-mimetic peptide was synthesized from amino
acids that improved the ability of HDL to protect LDL
against oxidation in animals with atherosclerosis [2]. L-4F
treatment resulted in reduced adiposity, evident by decreased
visceral fat content, in conjunction with improved energy
balance and metabolic homeostasis in HO-2 null mice. These
changes were further characterized by increases in HO-1 and
adiponectin levels along with enhanced cellular expression of
LKBI-pAMPK in the liver tissues.

2. Materials and Methods
2.1. Animal Protocol. All animal experiments followed an
institutionally approved protocol in accordance with the NIH
Guide for the Care and Use of Laboratory Animals. The HO2 null mice are direct descendents of the HO-2 mutants
produced [17]. These well-characterized HO-2 null mice
have a C57BL/6 × 129/Sv genetic background that was
used on age- and gender-matched controls. Homozygote
HO-2(−/−) null and B6/129SF2/J (WT) mice were used
for the studies. Mice were divided into three groups (10
mice/group): WT, HO-2(−/−) + vehicle, and HO-2(−/−) +
L-4F. Beginning at 20 weeks of age when the mice had
established diabetes, L-4F (i.e., Ac-D-W-F-K-A-F-Y-D-KV-A-E-K-F-K-E-A-F-NH2) synthesized from L-amino acids
as previously described (Stephen P 2008) at a dose of
200 μg/100 g daily in 2 mL vehicle, or vehicles (ABCT:
ammonium bicarbonate buﬀer at pH 7.4 containing 0.01%
Tween 20) were administered intraperitoneally (i.p.) for 6
weeks. Mice were fed a normal chow diet and had access to
water ad libitum. Glucose monitoring was performed using
an automated analyzer (Life scan Inc., Milpitas, CA, USA).
Blood pressure was measured by the tail cuﬀ method before
and every 7 days after L-4F administration. Body weights of
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HO-2(−/−) and WT mice at the beginning of the experiment
were 28 ± 2 g and 20 ± 2 g, respectively. Glucose levels
were 160 ± 20 and 121 ± 20 mg/dL for HO-2(−/−) and WT
mice, respectively. At the time of sacrifice the body weight of
all mice was measured. The subcutaneous and visceral fat in
the abdomen, mesenteric fat, and fat around the liver, kidney,
spleen, and heart were dissected free, pooled for each mouse
and weighed. Blood samples were collected in K3 EDTA tubes
at sacrifice, and the plasma was separated. Liver samples were
flash frozen in liquid nitrogen for further studies.
2.2. Western Blot Analysis. Frozen hepatic samples were pulverized in T-PER (ThermoFisher Scientific, Rockford, IL,
USA) homogenization buﬀer, rotated for 1 hour at 4◦ C, and
then centrifuged at 12,000 rpm for 25 minutes at 4◦ C. The
supernatant was collected and protein was quantified using
the BCA protein assay (Pierce Biotechnology, Inc., Woburn,
MA). Protein expression analysis was preformed through
immunoblotting with antibodies against HO-1 (Stressgen
Biotechnologies Corp., Victoria, BC, Canada), adiponectin,
pAKT, AKT, pAMPK, and AMPK (Cell Signaling Technology,
Inc. Beverly, MA, USA) were used. Imaging and quantification were done using the Odyssey imaging system (Li-Cor
Biosciences, Lincoln, NE, USA).
2.3. Real-Time Quantitative PCR. Total RNA was recovered
from liver following the Perfect Pure Tissue Kit (5Prime,
IN Gaithersburg, MD, USA) RNA extraction protocol with
DNase treatment. cDNA was made using the Improm Reverse Transcriptase kit (Promega, Madison, WI, USA). Primer sequences for mouse HO-1 were 5 -CAGCCCCACCAAGTTCAAAC-3 and 5 -TCAGGTGTCATCTCCAGAGTGTTC-3 , adiponectin 5 -AGCCGCTTATATGTATCGCTCA-3 and 5 -TGCCGTCATAATGATTCTGTTGG-3 ,
AMPK 5 -CGCAGACAGCCCCAAAG-3 and 5 -AGAGACTTGGGCTTCGTTGTGT-3 , LKB1 5 -TGCTGGACTCCGAGACCTTA-3 and 5 -CCTGCGCAGCTTTTTCTTC-3 ,
AKT 5 -GAACCGTGTCCTGCAGAACTCTAG-3 and 5 GTGGGTCTGGAATGAGTACTTGAG-3 , and GAPDH 5 CCAGGTTGTCTCCTGCGACT-3 and 5 -ATACCAGGAAATGAGCTTGACAAAGT-3 . The thermal cycling conditions were 95◦ C for 20 seconds followed by 40 cycles of 95◦ C
for 3 minutes, 60◦ C for 30 seconds, and finally 95◦ C for 15
seconds, 60◦ C for 1 minute, and 95◦ C for 15 seconds.
2.4. O2 − Production. liver samples were placed in scintillation vials (2 per vial) containing 1 mL of Krebs-HEPES
buﬀer, pH 7.4, and lucigenin (5 μmol/L) for 30 min at 37◦ C.
Lucigenin chemiluminescence was measured in a liquid scintillation counter (LS6000TA, Beckman Instruments) and superoxide production quantified as previously described [2].
2.5. Glucose and Insulin Tolerance Tests. After 6 h fast, mice
were injected intraperitoneally with glucose (2.0 g/kg body
weight). Blood samples were taken at various time points (0–
120 min), and blood glucose levels and serum insulin levels
were measured. For determination of insulin tolerance, mice
were injected intraperitoneally with insulin (2.0 U/kg). Blood
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Figure 1: Eﬀect of HO-2 deletion on body weight and adiposity. Figures showing wild-type (WT), HO-2 null (HO-2(−/−) ) and L-4F treated
HO-2(−/−) mice (HO-2(−/−) + L-4F) after 6 weeks of treatment. (a) Eﬀect of L-4F on body weight on HO-2(−/−) mice. (b) Eﬀect of L-4F on
subcutaneous body weight on HO-2(−/−) mice. (c) Eﬀect of L-4F on visceral body weight on HO-2(−/−) mice. Results are means ± SE, n = 6,
∗
P < 0.05 versus WT; # P < 0.05 versus HO-2(−/−) .

samples were taken at various time points (0–90 min), and
blood glucose levels were measured.
2.6. Measurement of HO Activity. Tissue HO activity, in liver
samples from WT, HO-2(−/−) treated and untreated mice,
was assayed as described previously [18, 19] using a technique in which bilirubin, the end product of heme degradation, was extracted with chloroform, and its concentration
was determined spectrophotometrically (dual UV/VIS beam
spectrophotometer lambda 25; PerkinElmer Life and Analytical Sciences, Wellesley, MA, USA) using the diﬀerence in
absorbance at a wavelength from λ460 to λ530 nm with an
absorption coeﬃcient of 40 mM−1 cm−1 . Under these conditions, HO activity was linear with protein concentration,
time-dependent, and substrate-dependent [18, 19].
2.7. Statistical Analyses. Statistical significance between experimental groups was determined by the Fisher method of
analysis of multiple comparisons (P < 0.05). For comparison
between treatment groups, the null hypothesis was tested by
a single-factor ANOVA for multiple groups or unpaired t-test
for two groups.

3. Results
3.1. Eﬀect of HO-2 Deletion on Body Weight, Fat Content,
Blood Pressure, and Metabolic Parameters. In Figure 1(a) we
show that HO-2 deletion significantly increased body weight
when compared to WT mice and was reversed after six weeks
of L4-F treatment. A similar pattern was observed in weight
reduction of subcutaneous and visceral fat by administration
of L4-F in HO-2(−/−) mice as shown in Figures 1(b) and 1(c).
Furthermore, we determined that the random blood glucose
levels in the HO-2 null mice were significantly increased
compared to WT and were reversed back to normal baseline
with L4-F treatment (Figure 2(a)). Both systolic and diastolic
blood pressures were significantly elevated in HO-2 null mice
as compared to WTs (P < 0.05) (Figure 2(b)). This increased
body weight, adiposity, and elevated blood pressure suggests
metabolic syndrome like phenotype in HO-2 KO mice,
which was successfully reversed by HO-1 induction.
To investigate if the metabolic syndrome, observed in
HO-2 null mice, is associated with insulin resistance, we
performed insulin sensitivity and glucose tolerance tests.
Insulin administration to WT, HO-2 null, and L4-F treated
HO-2 null mice produced a rapid decrease in glucose levels in
the WT and L-4F treated HO-2 KO mice compared to HO-2
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Figure 2: Eﬀect of L-4F on blood glucose, blood pressure, insulin sensitivity, and glucose tolerance in HO-2 null mice. (a) Blood glucose.
Values are means ± SE, n = 6, ∗ P < 0.05 versus WT; # P < 0.05 versus HO-2(−/−) . (b) Blood pressure values are means ± SE, n = 6, ∗ P < 0.05
versus respective WT, # P < 0.05 versus respective HO-2(−/−) . HO-2(−/−) . (c) Intraperitoneal insulin sensitivity (IPITT) and glucose tolerance
(IPGTT) (d) tests were performed as described in research designs and methods. Results are means ± SE, n = 6. (IPITT) ∗ P < 0.05 versus
WT, # P < 0.05 versus HO-2(−/−) , (IPGTT). ∗ P < 0.05 versus WT, # P < 0.05 versus HO-2(−/−) .

null (P < 0.05), suggesting improved sensitivity of HO-2 null
mice with L-4F treatment, decreasing from 333.7 ± 6.0 mg/dL
for HO-2 null mice to 84.7 ± 4.9 mg/dL in the L-4F treated
HO-2 null mice (Figure 2(c)). Plasma glucose levels at all
times were significantly elevated in the HO-2 null mice
compared to the L-4F treated HO-2 null mice. Glucose
administration to all mice rapidly increased the glucose
level after 30 min and remained elevated in the HO-2 null
mice, compared to the L4-F treated HO-2 null and WT mice
which returned to initial levels at 120 min (Figure 2(d)).

3.2. Eﬀect of HO-2 KO on Tissue Redox, HO-1 Expression,
and Activity. Analysis of lucigenin-detectable chemiluminescence demonstrated enhanced oxidative stress in hepatic
samples from HO-2 KO versus WT mice (P < 0.05). This
increase in O2 − generation was attenuated (P < 0.05) in
HO-2 null mice treated with L-4f for 6 wks (Figure 3(a)).
In Figure 3(b), we show that the HO-2 null mice express
significantly (P < 0.05) lower levels of HO-1 as compared to
WT mice; however levels are restored with L-4F treatment.
A daily injection of L-4F for 6 weeks also resulted in a
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Figure 3: Eﬀect of L-4F on redox status, HO-1 levels, and activity in HO-2 null mice. (a) Levels of superoxide produced in WT, HO-2(−/−)
and L-4F treated HO-2(−/−) mouse liver. Values are means ± SE, n = 6, ∗ P < 0.05 versus WT, and # P < 0.05 versus HO-2(−/−) . (b) Western
blot, densitometry analysis and (c) mRNA expression of hepatic tissues for HO-1 expression. Values are means ± SE, n = 6, ∗ P < 0.05 versus
WT, # P < 0.05 versus HO-2(−/−) (d). Eﬀects, L-4F on HO-1 activity measured as described in materials and methods. Results are means ±
SE, n = 6, ∗ P < 0.05 versus HO-2(−/−) .

significant increase in HO-1 mRNA levels compared to
the HO-2 null mice (Figure 3(c)). HO-2 deletion impairs
HO-1 inducibility leading to a decrease in HO activity. In
Figure 3(d) we show that treatment with L-4F in the HO-2
null mice significantly increases HO-1 activity.
3.3. Eﬀect of HO-2 KO on Hepatic Adiponectin and pLKB1/
pAMPK Signaling. Western blot analysis demonstrated that
HO-2 deletion is associated with significant decrease in the
expression of adiponectin when compared to age-matched
WT (Figure 4(a)). Treatment with L-4F increased these levels
by 2-fold to levels significantly higher than those measured in
HO-2 null mice (Figure 4(a)). Consistent with the changes in
protein shown in Figure 4(a), we show with real-time PCR
that adiponectin levels significantly increase with treatment
with L-4F compared to untreated in the HO-2 null mice
(Figure 4(b)). To elucidate the mechanism involved in the

changes observed with L-4F treatment, we determined expression and activity of signaling pathways that may be involved in the process. Interestingly, the expression of activated AMPK was regulated by HO-2 deletion since the HO-2
null mice expressed significantly lower levels of pAMPK
albeit normal levels of AMPK. L-4F restored the levels of
pAMPK in the HO-2 null mice without aﬀecting total AMPK
levels (Figure 4(c)). Furthermore, there was a significant
increase in LKB1 expression in the L-4F treated HO-2 null
mice (Figure 4(d)), which suggests that the AMPK/LKB1
pathway could play a role in the L-4F mediated resource of
HO-2(−/−) phenotype. In addition, to elucidate modulation
of AKT-dependent pathways by HO-1 induction via L4F, immunoblot assessment of pAKT/AKT was performed
which exhibited enhanced (P < 0.05) pAKT/AKT levels in
HO-2 KO (1.39 ± 0.12) versus WT (1.02 ± 0.09) mice. This
eﬀect of HO-2 deletion on pAKT expression was unaﬀected
by L-4F administration in HO-2 null mice (1.46 ± 0.14).
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Figure 4: Eﬀect of L-4F on adiponectin pAMPK and LKB1 expression in HO-2 null. L-4F was administered daily for 6 weeks and liver tissues
analyzed for adiponectin protein (a) and mRNA (b) expression. Protein bands were analyzed by densitometry and plotted against a relative
expression to actin. Results are means ± SE, n = 6, ∗ P < 0.05 versus WT, # P < 0.05 versus HO-2(−/−) . (c) Western blot and densitometry
analysis of hepatic tissues for pAMPK and AMPK. Values are means ± SE, n = 5, ∗ P < 0.05 versus WT, # P < 0.05 versus HO-2(−/−) . (d)
Expression for LKB1 in WT, HO-2 KO with and without L-4F. Values are means ± SE, n = 6, ∗ P < 0.05 versus WT, # P < 0.05 versus
HO-2(−/−) .

4. Discussion
The data presented here shows that treatment of HO-2 null
mice with L-4F rescues the key markers of metabolic syndrome via an increase in HO-1 and adiponectin through a
signaling mechanism involving the LKB1/AMPK signaling
pathway (Figure 5). Interestingly, L-4F had no eﬀect on activated AKT (pAKT), suggesting selectivity of L-4F to pAMPK.
First key finding presented here is in line with earlier
reports [4, 11] suggesting a role of HO-2 in mediating
HO-1 upregulation. HO-2 null mice were characterized by
disruption of metabolic homeostasis and displayed increased

body weight, adiposity, insulin resistance with elevated blood
pressure, and oxidative stress. Pathophysiological conditions
such as these have historically been shown to be associated
with increase in cellular defense mechanisms including HO1 [20]. HO-2, a constitutively expressed isoform, supports
sustenance of basal redox status in the cells, and its knockdown is not surprisingly met with oxidative stress. HO-1
induction, however, in this HO-2 knockdown state fails to
occur even in the presence of added pathophysiological insult
such as metabolic syndrome. These observations delineate
the essential role of HO-2 in stress-induced HO-1 induction.
This failure of HO-1 upregulation could further dampen
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Figure 5: Schematic, the upregulation of HO-1 and adiponectin levels by L-4F coincides with increased pAMPK and LKBI levels providing
a signaling mechanism by which L-4F rescues the metabolic phenotype and improves vascular function.

cellular defenses and contribute towards the phenotypic
alteration observed in these animals. Restoration of HO-1
expression and activity accompanied by phenotype reversal
further supports the role of deficient HO-1 in mediating,
at least partly, clinicopathological alterations observed in
HO-2 null state. Previous reports have documented physical
interactions of the two HO isoforms [21], which could
contribute towards HO-2-dependent induction of HO-1.
Second key observation of this study is the modulatory
eﬀect of heme-HO system on adiponectin and associated
metabolic signaling pathways and their role in alleviating
metabolic pathologies observed in an HO-2 KO state. One
major marker of obesity is inflammation, which produces an
excess of reactive oxygen species, specifically superoxide [11].
When there is chronic exposure to an excess of superoxide,
adiponectin and HO-1 levels decrease significantly and
contribute to the pathogenesis of insulin resistance [2, 4, 9,
12]. An increase in HO-1 levels increases adiponectin levels,
which is known to possess a vascular protective role, preserve
endothelial function, and improve insulin sensitivity through
glucose uptake [1, 9]. Treatment with L-4F is shown to
increase both HO-1 and adiponectin levels in vitro and
in vivo [2, 15] while decreasing superoxide (Figure 3(a)),
further supporting the idea that L-4F improves the phenotype in the metabolic syndrome mouse model through an
increase in insulin sensitivity and glucose tolerance.
L-4F treatment significantly increased pAMPK and LKB1
levels, all associated with improved insulin sensitivity [15]. PAMPK is known to act in the regulation of cell survival, protect against oxidative stress [15, 22–24], and, when activated,
contribute to glucose transport, fatty acid oxidation, and
increased mitochondrial function [2, 25]. It is known that

crosstalk between AMPK and AKT can regulate nitric oxide
bioavailability and vascular function [22, 23, 26]. However
L-4F did not aﬀect the protein expression or activation of
AKT, suggesting a pathway more specific to AMPK. LKB1 is a
serine-threonine kinase that directly phosphorylates AMPK
and decreases lipogenesis [4, 5, 8]. We show that L-4F induces
LKB1 in HO-2 null mice, indicating that HO-1 mediates
the transcriptional regulation of LKB1 by L-4F to activate
AMPK.
In conclusion, as depicted in the schematic (Figure 5),
the upregulation of HO-1 and adiponectin levels by L-4F
coincides with increased pAMPK and LKBI levels, providing
a signaling mechanism by which L-4F rescues the metabolic
syndrome phenotype and improves energy balance. Thus,
L-4F could provide as a beneficial drug treatment to complement conventional therapeutic of disease associated with
disruption of metabolic homeostasis.

Abbreviations:
HO-1/HO-2:
ROS:
EC-SOD:
NO:
AKT:
pAKT:
AMPK:
pAMPK:
O2 − :
LKB1:

Heme oxygenase 1, 2
Reactive oxygen species
Extracellular superoxide dismutase
Nitric oxide
Protein kinase B
Phosphorylated protein kinase B
AMP-activated protein kinase
Phosphorylated AMP-activated protein
kinase
Superoxide
Serine/threonine kinase 11.
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